BioCentury
ARTICLE | Clinical News

Biohaven falls on trigriluzole miss

October 2, 2017 11:45 PM UTC

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) lost $1.82 to $35.56 on Monday after reporting that trigriluzole (BHV-4157) missed the primary endpoint in a Phase IIb/III trial to treat spinocerebellar ataxia. CEO Vlad Coric told BioCentury the company will determine next steps for trigriluzole in the indication after analyzing data expected in 4Q18 from an open-label, 48-week extension of the trial.

On the 141-patient trial's primary endpoint, once-daily 140 mg oral trigriluzole improved mean Scale for the Assessment and Rating of Ataxia (SARA) score from baseline to week eight by -0.81 points vs. -1.05 points for placebo (p=0.52). Trigriluzole also missed the secondary endpoint of a greater proportion of patients who considered themselves "improved" on the Patient Global Impression of Change (PGI-C) vs. placebo (50.8% vs. 59.1%, p=0.28). ...